spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  basal cell carcinoma 

 HSMN NewsFeed - 19 Jun 2023
Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jan 2022
Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Apr 2021
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Feb 2021
The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Nov 2019
INHIBITOR Therapeutics Submits Investigational New Drug Application for Treatment of Patients with Late-Stage Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Nov 2019
Regeneron Provides Updates on Phase 3 Libtayo(R) (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Nov 2018
Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Aug 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI(R) and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Jul 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI(R) (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2018
Curis Announces FDA Fast Track Designation for Fimepinostat Development in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 May 2018
Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Dec 2017
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 15 Nov 2016
Blueprint Medicines Announces Appointment of Marion Dorsch, Ph.D. as Chief Scientific Officer and the Transition of Christoph Lengauer, Ph.D., MBA, to a Newly Created Executive Vice President Role
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Mar 2016
Curis Announces Expansion of Executive Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Mar 2016
The Netherlands' Radiotherapy Group is Country's First to Use Elekta's Esteya Electronic Brachytherapy to Treat Skin Cancer Patients
Devices Oncology
 HSMN NewsFeed - 21 Dec 2015
Oral REVLIMID(R) Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Jul 2015
FDA approves Novartis drug Odomzo(R) (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Nov 2014
Titan Pharmaceuticals Appoints Two New Board Members
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jun 2014
Curis Announces Executive Management Transition
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 May 2014
Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jul 2013
Celgene Will Discontinue Phase III ORIGIN(R) Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 May 2013
Curis Announces Approval of Erivedge(R) in Australia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Apr 2013
Curis Announces Erivedge(R) Receives Positive CHMP Opinion for Conditional Approval in European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Feb 2013
Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Nov 2012
Curis Announces $30 Million Secured Debt Financing to Support Development of Proprietary Pipeline
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2012
OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Oct 2012
iCAD Reports Growing Adoption of Its Xoft Electronic Brachytherapy System by Leading U.S. Regional Hospitals
Devices Oncology
 HSMN NewsFeed - 16 Aug 2012
Lucid, Inc. Reflects New Vision with Name Change to Caliber Imaging & Diagnostics, Inc.
Devices Diagnostics Oncology
 HSMN NewsFeed - 30 Jan 2012
Curis Announces FDA Approval of Erivedge(TM) (vismodegib) Capsule as First Treatment for Advanced Basal Cell Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Nov 2011
FDA Accepts Genentech’s New Drug Application For Vismodegib in Advanced Form of Skin Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Sep 2011
Genentech Submits New Drug Application to FDA for Vismodegib for Rare Form of Advanced Skin Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Aug 2011
Baxter Announces FDA Approval of ARTISS Fibrin Sealant for Use in Face-Lift (Facial Rhytidectomy) Procedures
Devices FDA
 HSMN NewsFeed - 21 Mar 2011
Genentech Announces Positive Pivotal Phase II Results for Hedgehog Pathway Inhibitor in Advanced Basal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Oct 2010
Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Aug 2010
T-Ray Science, Inc. Announces Reorganization
Devices Diagnostics Oncology Personnel
 HSMN NewsFeed - 27 May 2010
T-Ray Science, Inc. Announces Management Appointments
Devices Personnel
 HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 19 Jan 2009
A Milestone in Cancer Genetics: deCODE Discovers First Common Genetic Variants Affecting the Risk of Many Types of Cancer
Biopharmaceuticals Diagnostics Oncology
 HSMN NewsFeed - 27 Oct 2008
One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
Biopharmaceuticals
 HSMN NewsFeed - 4 Aug 2008
Meda Acquires European Businesses from American Valeant and Enters the Russian Market
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 11 Jun 2008
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2008
Valeant Pharmaceuticals Announces FDA Has Initiated Reconsideration of Generic Efudex(R) Approval
Biopharmaceuticals Generics Dermatology FDA
 HSMN NewsFeed - 14 Mar 2008
Genentech Provides Business Update at Annual Investment Community Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jan 2008
Exelixis and Bristol-Myers Squibb to Co-Develop XL139, an Inhibitor of the Hedgehog Pathway
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Nov 2007
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2007
New Data Show Obagi Medical Products' Nu-Derm Improves Scar Cosmesis Following Removal of Basal Cell Carcinoma versus Standard Treatment
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 16 Oct 2007
VivaScope(R) Confocal Imager May Eliminate Need for Routine Skin Biopsies for Dermatology Patients
Devices Dermatology
 HSMN NewsFeed - 18 Sep 2007
New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 29 May 2007
Peplin Appoints Chief Commercial Officer
Biopharmaceuticals Dermatology Oncology Personnel
 HSMN NewsFeed - 2 Jan 2007
Graceway Pharmaceuticals, LLC Announces Completed Acquisition of 3M Pharmaceuticals Business and FDA Extension of Aldara Exclusivities
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 9 Nov 2006
Graceway Pharmaceuticals to Acquire 3M Pharmaceuticals Business in North and Latin America
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Oct 2006
Curis, Inc. Announces Genentech Filing of Investigational New Drug Application for Systemic Administration of a Hedgehog Antagonist
Biopharmaceuticals
 HSMN NewsFeed - 11 Jul 2006
DUSA Pharmaceuticals Sues Additional Physicians and a Chemical Supplier for Infringement of its Levulan'R' Photodynamic Therapy Patents
Biopharmaceuticals Litigation
 HSMN NewsFeed - 30 Jun 2006
OXiGENE'S Board of Directors Names Experienced Biotech Executive, Richard Chin, M.D., as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 May 2006
Topical Hedgehog Agonist Accelerates Wound Healing in Diabetes
Biopharmaceuticals Wound Care
Return to NewsFeed  

 Additional items found! 33

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 33 additional stories matching:
basal cell carcinoma
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.